Oncolytics Biotech Initiates Enrollment for Phase II Cancer Trial
Posted on: Tuesday, 9 September 2008, 12:00 CDT
Oncolytics Biotech has initiated patient enrollment in a Phase II clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.
This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of Reolysin given intravenously in combination with a standard dosage of paclitaxel and carboplatin.
Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase II trial is to measure tumor responses and duration of response, and to describe any evidence of antitumor activity.
The secondary objective is to determine the safety and tolerability of Reolysin when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancers.
Monica Mita, principal investigator of the study, said: "We are extremely pleased to open the second disease-directed study with Reolysin. This study represents a promising option for patients with head and neck tumors refractory to standard chemotherapy and we are happy to have the opportunity to offer this option to our patients."
Source: Datamonitor
Related Articles
- Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans
- Biomodels' Oral Mucositis Expertise Speeds FDA Approval for ActoGeniX's Phase 1b Trial of AGO13 in Cancer Patients
- Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
- Ceragenix Completes Patient Visit Phase of Clinical Trial Study to Compare Efficacy of EpiCeram(R) to Elidel(R)
- Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
- Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105
- EpiCept Adds Study Center to Cancer Trial
- Vaccine's Promise Grows: Doses Might Protect Against Head, Neck Tumors, Study Says
- ImClone drug extends life in head, neck cancer patients
- Study Shows Patient Deaths Have Declined in Early Studies of New Cancer Drugs
 |
 |
User Comments (0)
RSS Feeds